Use of gevokizumab for the treatment of Behçet's disease

Bibliography

• Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999;341(17):1284-91
   PubMed Web of Science ®Google Scholar
• Ambrose NL, Haskard DO. Differential diagnosis and management of Behçet syndrome. Nat Rev Rheumatol 2013;9(2):79-89
   PubMed Web of Science ®Google Scholar
• Gul A. Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005;4(1):81-3
   PubMedGoogle Scholar
• de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009;61(10):1287-96
   PubMed Web of Science ®Google Scholar
• Gul A, Ohno S. HLA-B*51 and Behçet Disease. Ocul Immunol Inflamm 2012;20(1):37-43
   PubMed Web of Science ®Google Scholar
• Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol 1982;100(9):1455-8
   PubMed Web of Science ®Google Scholar
• Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013;45(2):202-7
   PubMed Web of Science ®Google Scholar
• Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010;42(8):703-6
   PubMed Web of Science ®Google Scholar
• Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010;42(8):698-702
   PubMed Web of Science ®Google Scholar
• Khairallah M, Accorinti M, Muccioli C, et al. Epidemiology of Behçet disease. Ocul Immunol Inflamm 2012;20(5):324-35
   PubMed Web of Science ®Google Scholar
• Verity DH, Marr JE, Ohno S, et al. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999;54(3):213-20
   PubMedGoogle Scholar
• Azizlerli G, Kose AA, Sarica R, et al. Prevalence of Behçet's disease in Istanbul. Turkey. Int J Dermatol 2003;42(10):803-6
   PubMed Web of Science ®Google Scholar
• Zhang ZL, He F, Shi YJ. Behçet's disease seen in China: analysis of 334 cases. Rheumatol Int 2013;33(3):645-8
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shahram F, Chams-Davatchi C, et al. Behçet's disease in Iran: analysis of 6500 cases. Int J Rheum Dis 2010;13(4):367-73
   PubMed Web of Science ®Google Scholar
• Kaneko F, Nakamura K, Sato M, et al. Epidemiology of Behçet's disease in Asian countries and Japan. Adv Exp Med Biol 2003;528:25-9
   PubMedGoogle Scholar
• Bang D, Lee JH, Lee ES, et al. Epidemiologic and clinical survey of Behçet's disease in Korea: the first multicenter study. J Korean Med Sci 2001;16(5):615-18
   PubMed Web of Science ®Google Scholar
• Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis Rheum 2009;61(5):600-4
   PubMed Web of Science ®Google Scholar
• Altenburg A, Papoutsis N, Orawa H, et al. [Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany -- current pathogenetic concepts and therapeutic possibilities]. J Dtsch Dermatol Ges 2006;4(1):49-64; quiz 5-6
   PubMedGoogle Scholar
• Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990;335(8697):1078-80
   PubMed Web of Science ®Google Scholar
• Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007;3(3):148-55
   PubMedGoogle Scholar
• Davatchi F, Assaad-Khalil S, Calamia KT, et al. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kotter I, Wallace GR, et al. Behçet's disease: ocular effects and treatment. Prog Retin Eye Res 2008;27(1):111-36
   PubMed Web of Science ®Google Scholar
• Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Behçet's disease: an international collaborative study. Br J Ophthalmol 2007;91(12):1579-82
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004;138(3):373-80
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008;67(12):1656-62
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40(4):769-74
   PubMedGoogle Scholar
• Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet's disease. Arthritis Care Res (Hoboken) 2010;62(12):1733-8
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322(5):281-5
   PubMed Web of Science ®Google Scholar
• BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988;20(3 Suppl 4):136-43
   PubMed Web of Science ®Google Scholar
• Binder AI, Graham EM, Sanders MD, et al. Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol 1987;26(4):285-91
   PubMedGoogle Scholar
• Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;1(8647):1093-6
   PubMed Web of Science ®Google Scholar
• Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 1992;76(4):241-3
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases. Clin Rheumatol 2006;25(4):482-6
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138(4):467-71
   PubMed Web of Science ®Google Scholar
• Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004;33(5):311-19
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 2011;129(3):288-94
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Ophthalmology 2010;117(7):1430-5
   PubMed Web of Science ®Google Scholar
• Sugita S, Kawazoe Y, Imai A, et al. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Arthritis Res Ther 2012;14(3):R99
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41(1):61-70
   PubMed Web of Science ®Google Scholar
• Benitah NR, Sobrin L, Papaliodis GN. The use of biologic agents in the treatment of ocular manifestations of Behçet's disease. Semin Ophthalmol 2011;26(4-5):295-303
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenc V, et al. Current and future treatments for Behçet's uveitis: road to remission. Int Ophthalmol 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial. Rheumatol Int 2008;29(1):53-7
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005;52(8):2478-84
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 2012;130(5):592-8
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in Behçet's disease. Invest Ophth Vis Sci 2011;52(1):476-84
   PubMed Web of Science ®Google Scholar
• Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 2010;18(3):226-32
   PubMed Web of Science ®Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007;21(6):824-5
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) 2012;51(10):1825-31
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behçet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13(3):246-52
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod Rheumatol 2008;18(3):306-8
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S, et al. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody. tocilizumab. Mod Rheumatol 2012;22(2):298-302
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11(8):633-52
   PubMed Web of Science ®Google Scholar
• Botsios C, Sfriso P, Furlan A, et al. Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008;149(4):284-6
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Borri M, et al. Successful use of canakinumab in a patient with resistant Behçet's disease. Clin Exp Rheumatol 2012;30(3 Suppl 72):S115
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease. Ann Rheum Dis 2012;71(9):1589-91
   PubMed Web of Science ®Google Scholar
• Geiler J, McDermott MF. Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther 2010;12(6):755-69
   PubMedGoogle Scholar
• Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs 2011;3(1):49-60
   PubMed Web of Science ®Google Scholar
• Gul A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann Rheum Dis 2012;71(4):563-6
   PubMed Web of Science ®Google Scholar
• Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20(9):1544-9
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174(5):1209-20
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147(11):3815-22
   PubMed Web of Science ®Google Scholar
• Blech M, Peter D, Fischer P, et al. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1beta. J Mol Biol 2013;425(1):94-111
   PubMed Web of Science ®Google Scholar
• Roell MK, Issafras H, Bauer RJ, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem 2010;285(27):20607-14
   PubMed Web of Science ®Google Scholar
• Owyang AM, Maedler K, Gross L, et al. XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology 2010;151(6):2515-27
   PubMed Web of Science ®Google Scholar
• Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012;35(8):1654-62
   PubMed Web of Science ®Google Scholar
• Donath MY, Weder C, Whitmore J, et al. XOMA 052, an anti-IL-10 antibody, in a double-blind, placebocontrolled, dose escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus - a new approach to therapy. Diabetologia 2008;51:S7-S
   Web of Science ®Google Scholar
• Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009;206(5):1029-36
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Ikejima T, Warner SJ, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987;139(6):1902-10
   PubMed Web of Science ®Google Scholar